Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TGM2 | P21980 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2305964 | 0.81 | RAB9A (0.47) | CES1KDM4EMAPTS1PR4HSP90AA1 | |
| SCHEMBL5740387 | 0.80 | CES1 (0.38) | CES1KDM4EMAPTS1PR4HSP90AA1 | |
| SCHEMBL7815590 | 0.79 | ALDH1A1 (0.44) | CES1KDM4EMAPTS1PR4HSP90AA1 | |
| SCHEMBL30829013 | 0.77 | ALDH1A1 (0.41) | CES1KDM4EMAPTS1PR4HSP90AA1 | |
| SCHEMBL3391317 | 0.77 | CES1 (0.67) | CES1MAPTHTTMCL1ALDH1A1 | |
| SCHEMBL734955 | 0.76 | CES1 (1.00) | CES1MAPTMCL1TGM2MEN1 | |
| SCHEMBL281586 | 0.75 | CES1 (0.55) | CES1KDM4EMAPTS1PR4HSP90AA1 | |
| SCHEMBL30397534 | 0.75 | CES1 (0.55) | CES1KDM4EMAPTS1PR4HSP90AA1 | |
| SCHEMBL11428923 | 0.74 | GSK3B (0.45) | KDM4EMAPTS1PR4HSP90AA1G6PD | |
| SCHEMBL31103242 | 0.73 | CES1 (0.67) | CES1MAPTMCL1TGM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007132280-A1 | ISATIN AND ITS DERIVATIVES FOR USE AS A MEDICAMENT | Szegedi Tudományegyetem (HU) | 2007-11-22 | — | — | WO | disclosed |
| US-7037909-B2 | Tetracyclic compounds as c-Met inhibitors | SUGEN, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005004808-A2 | TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20050014755-A1 | Tetracyclic compounds as c-Met inhibitors | SUGEN INC. | 2005-01-20 | — | — | US | disclosed |
| EP-0002624-B1 | 2-BENZAZEPINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1981-10-14 | — | — | EP | disclosed |
| EP-0002624-A1 | 2-Benzazepine compounds, processes for their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014755-A1 | Tetracyclic compounds as c-Met inhibitors | MET, RET, HGF | CES1 1228/4885KDM4E 1122/4885MAPT 3279/4885 |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CES1 1061/4885KDM4E 861/4885MAPT 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.